A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult Subjects With Schizophrenia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2018
At a glance
- Drugs TAK 831 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Takeda
- 31 Aug 2018 Biomarkers information updated
- 13 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Jan 2018 Status changed from not yet recruiting to recruiting.